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F O R E W O R D
There has been a growing interest in the marine derived bioactivecompounds in the recent years, and the functional foods, enriched
with natural ingredients have been proved to provide beneficial action
for human health. Marine derived bioactive components and the functional food ingredients
demonstrated to possess potential health benefits. High value secondary bioactive
metabolites from the marine organisms are attracting attention because of the growing
demand for new compounds of 'marine natural' origin, having potential applications in
pharmaceutical fields, and concerns about the adverse effects by synthetic drugs and their
derivatives. The pioneering R & D works at ICAR-Central Marine Fisheries Research Institute
on marine bioprospecting envisaged a systematic approach involving chemical profiling of
major species of marine organisms for bioactive pharmacophore leads for activity against
various diseases, and a library of molecules with bioactive potential. The research work in
this institute developed protocols to prepare various pharmaceutical leads, nutraceuticals/
functional food supplements enriched with lead molecules with different properties against
various drug targets for use against various life-threatening diseases.
ICAR-Central Marine Fisheries Research Institute is the pioneering marine research
institute in India to work in the frontier area of bioactive molecule discovery from marine
organisms as promising therapeutic agents against various diseases, aquatic food product
technology, and development of high value products for health management. This prestigious
research institute of Indian Council of Agricultural Research is working in the broad national
interest of producing high value bioactive leads from the marine organisms, which would
provide promising therapeutic agents against various diseases. This institute has developed
and commercialized the nutraceutical products CadalminTM Green Algal extract (CadalminTM
GAe) and Antidiabetic extract (CadalminTM ADe) as green alternatives to synthetic drugs to
combat rheumatic arthritic pains and type-2 diabetes, respectively to a leading
biopharmaceutical company in India. The anti-inflammatory nutraceutical Cadalmin™ Green
Mussel extract (Cadalmin™ GMe) from Asian green mussel Perna viridis has been
commercialized with Amalgam Group of Companies. CadalminTM Antihypercholesterolemic
extract (CadalminTM ACe) has been developed from seaweeds to combat dyslipidemia leading
to obesity, and the product was out-licensed to a leading Indian MNC in wellness and
obesity management. Antimicrobial therapeutic product from marine bacteria as oral
applicant has been developed and the product is in pipeline for commercialization. Seaweed-
derived natural template inspired synthetic derivatives as potential pharmacophores were
designed and developed. Several nutraceutical and cosmeceutical products from marine
organisms are in pipeline, and are being commercialized.
The objective of the National level ICAR Winter School on "Recent advances in bioactive
compounds from marine organisms and development of high-value products for health
management" is to provide up-to-date information and acquaint the participants with the
latest technologies on isolation and characterization of marine natural products of
pharmaceutical importance from marine organisms, general and advanced methods of
isolation procedures by chromatography, classification of organic compounds and their
characterization by advanced spectroscopic experiments. This program further aims to give
exposure to the chemical perspectives of marine organisms, primary and secondary bioactive
metabolites from fish and marine organisms to develop bioactive compounds and high-
value functional food products. Theory and practical classes will be conducted in these
areas to provide the participants a hands-on experience.
This ICAR Winter School is organized with the full funding support from ICAR, New
Delhi, and the twenty-five participants from various parts of India who are attending this
programme were selected after scrutiny of their applications based on their bio-data. They
are serving as academicians, such as Professors/Scientists, and in similar posts. The faculties
include the knowledgeable scientists and professors from various parts of India and abroad.
This training will enable the participants to efficiently carry out their academic programmes,
and to plan research on bioactive molecule discovery in their respective laboratories and
institutes so that they can formulate the strategies for research.
The Winter School on "Recent advances in bioactive compounds from marine organisms
and development of high value products for health management" is very ideal for the
current scenario of increasing lifestyle diseases and human health. Understanding the
importance of natural products in the health care system of India, ICAR-Central Marine
Fisheries Research Institute has reasonably contributed in the various aspects. The Manual
released on this occasion covers all aspects of marine natural products prepared by the
experts in their respective fields. I congratulate the Course Director of this programme, Dr.
Kajal Chakraborty and Head of the Marine Biotechnology Division, Dr. P. Vijayagopal, along
with other staff members of Marine Biotechnology Division and Central Marine Fisheries
Research Institute for their sincere efforts in bringing out the manual in time, and to arrange
the programme in a befitting manner.
A. Gopalakrishnan
Director, ICAR-Central Marine Fisheries Research Institute
Kochi, Kerala
P R E F A C E
Marine-derived bioactive components and the functional food ingredients with potentialhealth benefits are an emerging area of research. The rich diversity of flora and fauna
in the marine and coastal habitats of the Indian subcontinent represent an untapped reservoir
of bioactive compounds with valuable pharmaceutical and biomedical use. Considering the
underutilization of these groups of marine organisms, exploring bioactive compounds and
development of any biologically useful products have benefits as health products.
Comprehensive analyses demonstrated that during the last decade the average proportion
of bioactive compounds among the new compounds is declining, though there are a large
number of marine natural products yet to be explored. This may indicate that the research
level of bioactivity is not keeping up with the discovery of new compounds. Thus, the research
tools and methods for finding bioactivity need to be improved. The first improvement is
about methods of spectral and bioactivity-guided separation and purification of marine-
derived secondary metabolites, which combine the discovery of new compounds. These
improvements in technology are dependent upon the automation in spectroscopy, which
also allows the study of the functions of new compounds extracted from the target marine
organisms. Second, for the discovery of new lead compounds and artificial intelligence for
drug development evolved to a more mechanistic approach that targets specific molecular
lesions. Combined with high-throughput screening through a large number of drug targets,
bioactivity research against various life-threatening diseases will be effective in revealing
the potentially useful biological properties of marine natural products. Furthermore, the
discovery of new bioactive compounds from marine metabolites will form the basis for new
drug leads. Thus, the new compounds will absolutely compose an abundant resource for
future bioactivity research and drug development. Various medicinal and biomedical products
from marine flora and fauna provide a myriad of benefits for human health and multiple
life-threatening diseases, and therefore, are the attractive options for the food and
pharmaceutical industry. The increasing interest in marine-based functional food ingredients
and nutraceutical formulations in the last decade along with increased number of patents
filed/granted have appropriately demonstrated the possibilities of bioactive from marine
organisms to maintain and improve human health and well-being.
The present ICAR Winter School on "Recent advances in bioactive compounds from
marine organisms and development of high-value products for health management" is
designed to acquaint the participants with the advances in marine bioactive compounds
with emphasis on the latest technologies on isolation and characterization of marine natural
products of pharmaceutical importance. The course is planned in such a way that it covers
both theoretical and practical aspect of recent advances in bioactive compounds from marine
organisms. This programme will strengthen the knowledge of participants with regard to
the general and advanced methods of isolation procedures by chromatography, and their
characterization by advanced spectroscopic experiments aspects.
I wish to thank the Education Division of Indian Council of Agricultural Research for
giving us an opportunity to organize this ICAR Winter School. We are grateful to Dr. A.
Gopalakrishnan, Director, ICAR-Central Marine Fisheries Research Institute, for his guidance,
continuous interest in the course and providing all necessary facilities. I am highly obliged
to Dr. P. Vijayagopal, Head, Marine Biotechnology Division for his guidance and support for
the programme. All the scientists of Marine Biotechnology Division, technical staff, supporting
staff and research scholars supported us in organizing the ICAR Winter School. I recall with
gratitude the marvellous effort and help in preparing this manual by Minju Joy, Research
Scholar of Marine Biotechnology Division. I take this opportunity to thank all the faculty
members who have devoted their valuable time and contributed material for the preparation
of the manual. I am confident that the Course Manual would aid the participants to enhance
their knowledge and competence in the area of marine bioactive compounds and their
applications for the development of high-value products for health management.
Kajal Chakraborty
January, 2018 Course Director
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1
There has been a growing interest in functional foods (or nutraceuticals) in recent years,
and the functional foods, enriched with natural ingredients have been proved to provide
beneficial action for human health. Marine derived bioactive components and the functional
food ingredients demonstrated to possess health benefits. High value secondary bioactive
metabolites from the marine organisms are attracting attention because of the growing
demand for new compounds of ‘marine natural’ origin, having potential applications in
pharmaceutical fields, and concerns about the toxic effects by synthetic drugs and their
derivatives. The R & D works at ICAR- Central Marine Fisheries Research Institute on marine
bioprospecting envisaged a systematic approach involving chemical profiling of major species
of marine organisms for bioactive pharmacophore leads for activity against various oxidative
stress-induced diseases with a focus on hypercholesterolmia, hypertension, diabetes,
inflammation, hypothyroidism, and a library of molecules with bioactive potential. This
research work also developed protocols to prepare various nutraceuticals/functional food
supplements enriched with lead molecules with different properties against various drug
targets for use against various lifestyle disorders. Combined with high throughput screening
through a large number of drug targets, bioactivity research against these diseases will be
effective in revealing the potentially useful biological properties of marine natural products.
Furthermore, the discovery of new bioactive compounds from marine metabolites will form
the basis for new drug leads. Thus, the new compounds will absolutely compose an abundant
resource for future bioactivity research and drug development.
MIRACLE CURE OF SEVERAL LIFE THREATENING DISEASES: NUTRACEUTICALS FROM
MARINE ORGANISMS
The rich diversity of marine organisms represents an untapped reservoir of bioactive
compounds with valuable pharmaceutical and biomedical use. The pioneering research
work at ICAR-Central Marine Fisheries Research Institute envisages a systematic approach
involving chemical profiling of major species of mollusks, seaweeds and seaweed-associated
heterotrophs for lead pharmacophores coupled with evaluation of target biological activities
against different disease models, for example, 3-hydroxy-3-methylglutaryl coenzyme A
reductase, type-2 diabetes modulators (dipeptidyl peptidase-4, protein tyrosine phosphatase
1B), angiotensin-I, inflammatory cyclooxygenases and lipoxygenases. Optimized physical/
chromatographic procedures have been developed by this institute to isolate and purify
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The research works at ICAR- Central Marine Fisheries Research Institute developed a
hitherto unraveled database of marine organisms with small molecular weight bioactive
molecules responsible to combat various life-threatening diseases. ICAR-Central Marine
Fisheries Research Institute is pioneering marine research institute in India to work in the
frontier area of marine bioprospecting/bioactive molecule discovery from seaweeds/
mollusks/marine heterotrophs and development of high value nutraceutical products as
dietary supplements and health management. This prestigious marine fisheries research
institute of Indian Council of Agricultural Research (ICAR) has developed and commercialized
the nutraceutical products CadalminTM Green Algal extract (CadalminTM GAe) and Antidiabetic
extract (CadalminTM ADe) as green alternatives to synthetic drugs to combat rheumatic
arthritic pains and type-2 diabetes, respectively to Celestial Biolabs Limited, Hyderabad,
a leading biopharmaceutical company in India with Rs. 5,00,000/- license fee along with
5% royalty. The anti-inflammatory nutraceutical Cadalmin™ Green Mussel extract (Cadalmin™
GMe) from Asian green mussel Perna viridis has been commercialized with Amalgam Group
of Companies with a royalty of 5% on annual sale basis. The active principles in Cadalmin™
GMe isolated from P. viridis exhibited potential capacities to inhibit experimentally induced
inflammation, and can act as dual inhibitors of membrane arachidonate oxygenation by
cyclooxygenase-2 (COX-2) and lipoxygenase (5-LOX) pathways, thus decreasing pro-
inflammatory prostaglandin (PGE2 and PGF2á)/leukotriene synthesis and down-regulating
the inflammatory sequence. CadalminTM Antihypercholesterolemic extract (CadalminTM ACe)
has been developed from seaweeds to combat dyslipidemia and obesity, and the product
was out-licensed to VLCC Personal Care Limited, a leading Indian MNC in wellness and
obesity management in particular, with manufacturing facilities in India and Singapore).
Antimicrobial therapeutic product from seaweed-associated bacterium as oral applicant
has been developed and the toxicity studies are being carried out. The lead molecules with
action against angiotensin converting enzyme-I, from seaweeds were isolated, and added
to a nutraceutical product that is being out-licensed. Seaweed-derived natural template
Nutraceuticals developed by ICAR-Central Marine Fisheries Research Institute for use against type-2
diabetes, obesity/dyslipidemia and rheumatoid arthritis
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inspired synthetic derivatives as potential pharmacophores with potential antibacterial
activities against methicillin-resistant Staphylococcus aureus and anti-angiotensin-I inhibitory
activities were designed and developed. Several cosmeceutical products from seaweeds
are in pipeline, and are being commercialized.
ANTIARTHRITIC NUTRACEUTICAL: CADALMINTM GREEN MUSSEL EXTRACT
(CADALMINTM GME)
Cadalmin™ Green Mussel extract (Cadalmin™ GMe) contains 100% natural marine
bioactive anti-inflammatory ingredients extracted from Asian green mussel P. viridis. The
nutraceutical product is effective to combat chronic joint pain, arthritis/ inflammatory
diseases. The active principles in Cadalmin™ GMe isolated from P. viridis exhibited potential
capacities to inhibit experimentally induced inflammation, and can act as dual inhibitors of
membrane arachidonate oxygenation by cyclooxygenase-2 (COX-2) and lipoxygenase
pathways, thus decreasing pro-inflammatory prostaglandin (PGE2 and PGF2á)/leukotriene
synthesis and down-regulating the inflammatory sequence. In vivo mammalian model studies
revealed that this nutraceutical product showed considerable inhibition on inflammation
after sixth hour, illustrating that CadalminTM GMe is potent but relatively slow-acting anti-
inflammatory agent. This product is free from deleterious trans fatty acids, free radicals/
free radical adducts/low molecular weight carbonyl compounds, and has been proved to
be safe from a long term preclinical/toxicity studies on the experimental subjects.
CadalminTM Green Mussel extract (CadalminTM GMe) for use against joint pain and arthritis
Cadalmin™ Green Mussel extract (Cadalmin™ GMe) contains 100% natural marine
bioactive anti-inflammatory ingredients extracted from green mussel Perna viridis. The
product is effective to combat arthritic pain and inflammatory diseases, and effective green
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alternative to synthetic non steroidal anti-inflammatory drugs and other products available
in the market. The active principles in Cadalmin™ GMe isolated from P. viridis were found to
competitively inhibit inflammatory cyclooxygenases (COX-1,2) and lipoxygenase (5-LOX) in
inflammation and oxidative stress reaction, resulting in decreased production of pro-
inflammatory prostaglandins and leukotrienes. In vivo animal model studies revealed that
active principles effectively suppressed the edema produced by the histamine, which indicates
that they exhibit its anti-inflammatory action by means of either inhibiting the synthesis,
release or action of anti-inflammatory mediators. CadalminTM GMe is an indigenous product,
and is highly cost effective and more effective in terms of its activity with that of the imported
products available in the market. Till date no medications are available to combat arthritic
pain. The available options available are knee replacement or painkillers, which have multiple
adverse effects on human health.
STATUS OF COMMERCIALIZATION
CadalminTM GMe has been commercialized during 2012 with Amalgam Group of
Companies. This is the first nutraceutical produced by an institute of Indian Council of
Agricultural Research (ICAR). This product is commercially produced and marketed by
Accelerated Freeze Drying Company Pvt. Ltd. under their brand name “Musseltone®”.
NUTRACEUTICAL PRODUCTS FROM SEAWEEDS
The seaweeds contain a large assemblage of species that predominate in the coastal shelf areas
of Indian subcontinent
MIRACLE CURE OF SEVERAL LIFE THREATENING DISEASES: NUTRACEUTICALS FROM
SEAWEEDS
The rich diversity of seaweeds represents an untapped reservoir of bioactive compounds
with valuable pharmaceutical and biomedical use. The pioneering research work at ICAR-
Central Marine Fisheries Research Institute envisages a systematic approach involving
chemical profiling of major species of seaweeds for lead pharmacophores coupled with
evaluation of target biological activities against different disease models, for example, 3-
hydroxy-3-methylglutaryl coenzyme A reductase, type-2 diabetes modulators (dipeptidyl
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peptidase-4, protein tyrosine phosphatase-1B), angiotensin-I, inflammatory cyclooxygenases
and lipoxygenases. Optimized physical/chromatographic procedures have been developed
by this institute to isolate and purify the molecules with target bioactivities.
Nutraceuticals developed by ICAR-Central Marine Fisheries Research Institute for use against type-2
diabetes, obesity/dyslipidemia and rheumatoid arthritis
The research works at ICAR-Central Marine Fisheries Research Institute developed a
hitherto unraveled database of seaweeds with small molecular weight bioactive molecules
responsible to combat various life-threatening diseases. This research work also relates to
develop protocols to prepare nutraceutical products enriched with lead pharmacophores
with different properties against various drug targets for use against obesity/dyslipidemia,
hypertension, diabetes, and inflammatory disorders. The research works carried out in the
institute developed natural anti-inflammatory supplements enriched with lead molecules
as neutraceutical CadalminTM Green Algal extract (CadalminTM GAe) from seaweeds as effective
green alternative to the synthetic drugs available in the market to combat rheumatic arthritic
pains. This product has been out-licensed to the biopharmaceutical company for commercial
production and marketing in India and abroad. The research efforts to isolate the lead
molecules with action against type-2 diabetes led to the development of a nutraceutical
product CadalminTM Antidiabetic extract (CadalminTM ADe) from marine algae that has been
out-licensed to leading Biopharma Company based at Hyderabad. CadalminTM
Antihypercholesterolemic extract (CadalminTM ACe) developed from seaweeds to combat
dyslipidemia and obesity, and the product is being out-licensed to a pharmaceutical company.
A HEALING TOUCH OF MOTHER NATURE
Seaweed derived bioactive components and the functional food ingredients with
potential health benefits are an emerging area of research. Various nutraceutical or functional
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food supplements and biomedical products from seaweeds provide a myriad of benefits
for human health and multiple life threatening diseases, and therefore, are the attractive
options for the pharmaceutical and healthcare industry. Novel secondary bioactive
metabolites from these ocean herbs are attracting attention because of the growing demand
for new compounds of ‘marine natural’ origin, having potential applications in pharmaceutical
fields, and concerns about the toxic effects by synthetic drugs and their derivatives.
Comprehensive analyses
demonstrated that during the last
decade the average proportion of
bioactive compounds among the new
compounds is declining, though there
are a large number of marine natural
products yet to be explored. This may
indicate that the research level of
bioactivity is not keeping up with the
discovery of new compounds. Thus, the
research tools and methods for finding
bioactivity need to be improved. The
first improvement is about methods of
nuclear magnetic resonance/mass
spectroscopy and bioactivity-guided separation and purification of marine-derived small
molecular weight secondary metabolites, which combine the discovery of new compounds.
These improvements in technology are dependent upon the automation in spectroscopy,
which also allow the study of the functions of new compounds extracted from the target
organisms. Second, for the discovery of new lead compounds for drug development,
screening for quantitative structure-activity relationship analyses and artificial intelligence
evolved to a more mechanistic approach that targets specific molecular lesions. Combined
with high throughput screening through a large number of drug targets, bioactivity research
against hypertension, type-2 diabetes, hypercholesterolmia, obesity/dyslipidemia, type-2
diabetes, and inflammation will be effective in revealing the potentially useful biological
properties of seaweed-derived marine natural products. Furthermore, the discovery of new
bioactive compounds from seaweeds will form the basis for new drug leads. Thus, the new
compounds will absolutely compose an abundant resource for future bioactivity research
and drug development. Recently, efforts are underway to exploit the bioactive leads from
the natural origin for use as food supplements in the food and pharmaceutical industry.
These naturally derived antioxidant leads are the preferred alternatives to the synthetic
derivatives due to their safety, sustainability and effectiveness. The long history of the usage
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seaweeds in the part of their staple diet of the people from Korea, Japan, China etc.
demonstrates their nutritional and health supplementing qualities. There are reports that
different genera of seaweeds mainly belonging to Sargassum, Porphyra, Ecklonia, Laminaria
etc have been used in Chinese medicine to treat against different diseases. Seaweeds,
especially Laminaraia spp were used to treat against goitre because of its richness in iodine
in China and Europe. These studies demonstrate the beneficial effect of seaweeds or seaweed
derived compounds in pharmaceutical industry.
ICAR-CENTRAL MARINE FISHERIES RESEARCH INSTITUTE: A PIONEERING INSTITUTE
IN INDIA TO DEVELOP A SERIES OF NUTRACEUTICAL PRODUCTS FROM SEAWEEDS
ICAR-Central Marine Fisheries Research Institute is the pioneering marine research
institute in India to work in the frontier area of marine bioprospecting/bioactive molecule
discovery from seaweeds and development of high value nutraceutical products as dietary
supplements and health management. This prestigious marine fisheries research institute
of Indian Council of Agricultural Research (ICAR) has developed and commercialized the
nutraceutical products CadalminTM Green Algal extract (CadalminTM GAe) and Antidiabetic
extract (CadalminTM ADe) as green alternatives to synthetic drugs to combat rheumatic
arthritic pains and type-2 diabetes, respectively. CadalminTM Antihypercholesterolemic extract
(CadalminTM ACe) has been developed from seaweeds to combat dyslipidemia and obesity,
and the product is being out-licensed to a pharmaceutical company. Semisynthetic C-4/C-
6 methylene-polycarboxylate cross-linked hybrid drug delivery system and a topical
antibacterial formulation have been developed from seaweeds, and were found to be
comparable with commercially available products. The lead molecules with action against
angiotensin converting enzyme-I, from seaweeds were isolated, and added to a nutraceutical
product that is being out-licensed. Seaweed-derived natural template inspired synthetic
derivatives as potential pharmacophores with potential antibacterial activities against
methicillin-resistant Staphylococcus aureus and anti-angiotensin-I inhibitory activities were
designed and developed. Several cosmeceutical products from seaweeds are in pipeline,
and are being commercialized.
A GREEN REMEDY NUTRACEUTICAL FOR TYPE-2 DIABETES FROM SEA: ICAR-CMFRI’S
CADALMINTM ANTIDIABETIC EXTRACT (CADALMINTM ADE)
Diabetes mellitus is a metabolic disorder which affects the endocrine system of the
body, characterized by defects in carbohydrate, lipid, and protein metabolism. Globally the
frequency of disorder is rising gradually; patients suffering from this disorder are unable to
turn out or respond properly to insulin produced in the body. It was estimated that 246
million persons in the world suffered from type 2 diabetes in 2015 and that this number will
reach at least 380 million in 2025. The number of diabetic patients is rapidly rising in most
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parts of the world. People with type 2 diabetes are often
sedentary, obese, middle-aged adults with an increased risk
of macrovascular disease, retinopathy, nephropathy,
neuropathy, and hypertension. These health complications
lead to increased morbidity and premature death. Type-2
diabetes receives more attention than type-1 diabetes because
it is considered to be a preventable disease. Type 2 diabetes
is caused by an imbalance between blood sugar absorption
and insulin secretion. Post-prandial hyperglycemia plays an
important role in development of type-2 diabetes.
Controlling plasma glucose levels are essential for
delaying or preventing type-2 diabetes. While efficient in
attenuating the rise in blood glucose levels in many patients,
the continuous use of the synthetic drugs is often associated
with undesirable side effects, such as liver toxicity and adverse
gastrointestinal symptoms. It is for this reason that there is a need for natural alternatives
which have no adverse or unwanted secondary effects. Dietary ingestion of seaweeds has
been shown to decrease diabetic complications in human and also have strong antioxidant
properties. It is, therefore, that a search of safer and effective alternatives to synthetic drugs
to combat type-2 diabetes led the scientists of ICAR-Central Marine Fisheries Research
Institute to investigate into the seaweeds, which are natural bounty of sea, for valuable
secondary metabolites, which are anti-diabetic in nature, and can offer relief to type-2
diabetes. A concerted research in this area led them to develop a 100% vegetarian
nutraceutical CadalminTM Antidiabetic extract (ADe) from selected seaweeds. CadalminTM
ADe contains 100% natural marine bioactive ingredients from selected seaweeds by a
patented technology. The bioactive ingredients in CadalminTM ADe competitively inhibit
dipeptidyl peptidase-4 and tyrosine phosphatase 1B thereby hindering the occurrence of
type-2 diabetes. Type-2 diabetes and obesity are characterized by resistance to hormones
insulin, possibly due to attenuated or diminished signaling from the receptors. A large
body of data have identified protein tyrosine phosphatase 1B (PTP1B) as a major negative
regulator of insulin signaling. Pharmacological agents capable of inhibiting the negative
regulator(s) of the signaling pathways like PTP 1B are expected to potentiate the action of
insulin and therefore be beneficial for the treatment of Type 2 diabetes. Antidiabetic extract
inhibits tyrosine phosphatase 1B (PTP1B) thereby hindering the occurrence of type-2 diabetes.
Another mode of action of Antidiabetic extract is inhibition of dipeptidyl peptidase-4 (DPP-
4), which is an antigenic enzyme expressed on the surface of most cell types and is associated
with immune regulation and signal transduction. DPP-4 inactivates the incertins GLP-1 and
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GIP by removing amino acids from these peptide hormones. GLP-1 and GIP are essentially
required for insulin secretion from the â-cells of pancreas. CadalminTM Antidiabetic extract
has no side effects (LD50 > 5000 mg/kg BW) as proved from the preclinical and acute/long
term chronic toxicity studies on experimental subjects. Preclinical trials showed no toxicity
related significant changes in renal or hepatic function, hematological indices and serum
biochemical parameters in the experimental subjects. The results also demonstrated a lack
of test substance-related general organ or systemic toxicity and hypoglycaemic disorders
following oral administration at a dose as high as 2000 mg/kg/d. The active ingredients in
the product were packed in plant-based capsules to meet the dietary needs of vegetarians.
CadalminTM ADe has a promising consumer appeal, and market potential especially for the
large vegetarian population in India and abroad. The unique biochemical engineering
techniques adopted to retain antidiabetic activities in preparation of CadalminTM ADe assures
higher shelf life. CadalminTM ADe has been officially released by the Hon’ble Union Minister
of Agriculture, Shri Radha Mohan Singh on 26th July 2015 at a function in Patna during the
ICAR Foundation Day. This product has been commercialized with a pharmaceutical company
and ICAR-CMFRI is in search of more commercial partners for wider dissemination of the
product in the marketplace.
CADALMINTM GREEN ALGAL EXTRACT (CADALMINTM GAE): A VEGETARIAN
NUTRACEUTICAL DEVELOPED FROM SEAWEEDS FOR USE AGAINST JOINT PAIN AND
ARTHRITIS
Arthritis represents a major health problem and its global
burden is rising at an alarming rate with millions of people
suffering from this disease due to various reasons. Many of
the allopathic prescriptions include Non Steroidal Anti-
Inflammatory Drugs (NSAIDs) and cyclooxygenase inhibitors
used in controlling arthritic conditions have known side
effects, especially with long term usage. About 25% of the
users experience some kind of side effect and 5% develop
serious health consequences such as stomach bleeding,
stroke, and acute renal failure. The New England Journal of
Medicine reports that “anti-inflammatory drugs (prescription
and over-the-counter, which include Advil®, Motrin®,
Aleve®, Ordus®, Aspirin, and over 20 others) alone cause over 16,500 deaths and over
103,000 hospitalizations per year in the US”, according to a review article published in the
New England Journal of Medicine.
The side-effects of synthetic drugs led the scientists of ICAR-Central Marine Fisheries
Research Institute to investigate into natural products for safer and effective alternatives.
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Scientists at ICAR-Central Marine Fisheries Research Institute identified the seaweeds, which
are natural bounty of sea, to possess valuable compounds that can offer relief to arthritis
and associated joint pain.
CadalminTM Green Algal extract (CadalminTM GAe) contains a unique blend of 100%
natural marine bioactive anti-inflammatory ingredients extracted from selected seaweeds
with a patented ecofriendly “green” technology. The product is effective to combat arthritic
pain and inflammatory diseases in human beings. The active principles in CadalminTM GAe
competitively inhibit pro-inflammatory mediators, resulting in decreased production of
inflammatory prostaglandins and leukotrienes, and its activity was found to be superior to
some of the synthetic non steroidal anti-inflammatory drugs available in the market. A
lower cycloxygenaseI/lipoxygenaseV and cycloxygenaseI/II (<1.0), simultaneous inhibition of
cycloxygenaseII and lipoxygenaseV enzymes and significant in vivo activity indicate higher
selectivity and lower side-effect profiles of CadalminTM GAe as compared to the synthetic
non-steroidal anti-inflammatory drugs. Long term animal model experiments proved the
efficiency and safety of this nutraceutical. CadalminTM GAe suppresses the edema produced
by histamine, and exhibits its anti-inflammatory action by means of either inhibiting the
synthesis, release or action of anti-inflammatory mediators. The mean lethal dose (LD50) of
CadalminTM GAe was found to be greater than 4000 mg/kg body weight of the mammalian
subjects that indicate the safety of the product. As part of the preclinical assay of the product,
feeding of CadalminTM GAe even at a dose upto 2500 mg/kg body weight did not induce
significant change in body weights, hematological indices, histopathological, and serum
biochemical parameters between the control and treated groups indicating that it has no
toxicity to the mammalian subjects.
CadalminTM GAe is an indigenous product, and is highly cost effective and more effective
in terms of its activity with that of the imported products available in the market. Till date no
medications are available to combat arthritic pain. The available options available are knee
replacement or painkillers, which have multiple adverse effects on human health. Also there
are technologies like creams/aurvedic medicines that are either not effective or not
scientifically documented. CadalminTM GAe is a solution to these problems. This nutraceutical
has been developed to concentrate the anti-inflammatory bioactive compounds/principles
in a capsule (400 mg), whereas the active ingredients therein competitively inhibit pro-
inflammatory mediators, resulting in decreased production of inflammatory prostaglandins
and leukotrienes. CadalminTM GAe was distributed to the patients suffering with chronic
joint pain and arthritis, and questionnaire and clinical trial-based studies revealed that more
than 98% of the respondents were satisfied with the product with about 70-85% relief in
joint pain and arthritis. None of the respondents reported any side effects. The diagnostically
useful autoantibody termed as Rheumatoid Factors (RFs), which are the most useful
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prognostic marker for rheumatoid arthritis, significantly reduced from more than 300 IU/
mL to less than 20-35 IU/mL within a period of two months of consuming the product. The
mean lethal dose (LD50) of Cadalmin
TM GAe was found to be greater than 4000 mg/kg body
weight of the mammalian subjects that indicate the safety of the product unlike the painkillers
available in the market. This product has been commercialized with a pharmaceutical
company and ICAR-CMFRI is in search of more commercial partners for wider dissemination
of the product in the marketplace.
CADALMINTM ANTIHYPERCHOLESTEROLEMIC EXTRACT (CADALMINTM ACE):
ANTIOBESITY NUTRACEUTICAL FROM SEAWEEDS
Obesity is a medical condition in which excess body
fat has accumulated to the extent that it may have
a negative effect on health. Obesity is one of the
leading preventable causes of death worldwide. The
prevalence of obesity has significantly increased
over the last several decades. Increased abdominal
(visceral) fat accumulation and obesity is associated
with type-2 diabetes, abnormalities in lipid
metabolism and coronary artery disease.
Approximately 70% of obese patients are
dyslipidemic, which include elevated serum
triglyceride (hypertriglyceridemia), reduced high-
density lipoprotein, and increased small, dense low-
density lipoprotein (LDL) particle number. The
treatment of the dyslipidemia is focused on lipid-
lowering therapy by statin treatment, which has
proved adverse effects including drug-induced insulin resistance, chronic inflammation,
reduced immunity (by depletion of  CoQ10) and increased cancer risk.
The side-effects of synthetic drugs led the scientists of ICAR-Central Marine Fisheries
Research Institute to investigate into natural alternatives from seaweeds for safer and effective
alternatives. Scientists at this institute identif ied seaweeds, which possess valuable
compounds that can serve as natural remedy for obesity and dyslipidemia. CadalminTM
Antihypercholesterolemic extract (CadalminTM ACe) is nutraceutical product developed by
ICAR-Central Marine Fisheries Research Institute, as natural remedy for obesity and
dyslipidemia from seaweeds, which are commonly available in the Indian coastal waters.
Bioactive pharmacophore leads from seaweeds were used to develop the nutraceutical
product, and were found to inhibit hydroxymethyl glutaryl coenzyme A reductase, various
target receptors and other rate limiting enzymes, which are responsible to cause obesity
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and dyslipidemia. CadalminTM ACe can be administered to regulate clinical indicators leading
to dyslipidemia or obesity, total adipose tissue and visceral fat, triglycerides, cholesterol,
both good and bad, known as HDL, VLDL and LDL. CadalminTM ACe contains 100% natural
marine bioactive ingredients from selected seaweeds by a patented technology, and would
be made available in 400 mg capsules. The nutraceutical does not have any side effects as
established by detailed preclinical trials. CadalminTM ACe is the only product made by 100%
natural marine bioactive ingredients from seaweeds as a natural remedy of obesity and
dyslipidemia.  The active ingredients in the product would be packed in plant-based capsules
to meet the dietary needs of the large vegetarian population in India and abroad. Large
scale extraction of the active principles from the raw material was optimized in a factory
unit. The total yield of the active principles from the raw material in the factory unit was
found to be greater than 20%, which demonstrated the commercial feasibility of the
nutraceutical product. The product is being out-licensed to the pharmaceutical company.
Shri Justice P. Sathasivam, Hon’ble Governor of Kerala, released the product during the
inaugural ceremony of the Platinum Jubilee celebrations of the ICAR-Central Marine Fisheries
Research Institute at the Headquarters in Kochi on 18th February 2017. This product is
commercialized with VLCC during 23rd may 2017.
CONCLUSIONS
Marine derived bioactive components with potential health benefits are an emerging
area of research. Considering their underutilization, exploring bioactive compounds and
development of any biologically useful products has duel benefits-as health products and
their commercial farming of mollusks and seaweeds in coastal habitats, resulting in C-
sequestration and C-budgeting in a scenario where climate change may pose a serious
threat in future. Development of value-added products from these underutilized species
will also promote their farming in coastal habitats, which has not been seriously explored
earlier due to the lack of knowledge about their commercial importance. ICAR-Central Marine
Fisheries Research Institute has devoted research program to develop various health products
from marine organisms towards their utilization based on the National Policy to harness the
potential of this natural wealth of Indian coastal waters. ICAR-Central Marine Fisheries
Research Institute is also in the process of developing more health products from the
underutilized seaweeds for treatment against thyroid disorder, hypertension and other
lifestyle diseases. Several cosmeceutical products, such as seaweed-based antimicrobial
ointment, hybrid drug delivery system are also in the pipeline, and are being commercialized.
This prestigious marine fisheries research institute of Indian Council of Agricultural Research
(ICAR) is working in the broad national interest of producing high value nutraceutical
products/pharmaceutical leads from the marine organisms, which will provide promising
therapeutic agents against various diseases.
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SUGGESTED READINGS
A process to concentrate anti-inflammatory principles from green mussel Perna viridis L. and a product
incorporating these ingredients. 2065/CHE/2010 (Indian patent application).
A product containing anti-inflammatory principles from green mussel Perna viridis L. and a process thereof
2066/CHE/2010 (Indian patent application).
A process to prepare antioxidant and anti-inflammatory concentrates from brown and red seaweeds and a
product thereof 2064/CHE/2010 (Indian patent application).
A Process to isolate anti-inflammatory principles from green mussel Perna viridis L. to prepare a stabilized
nutraceutical supplement against inflammatory disorders and a product thereof 5198/CHE/2012 (Indian
patent application).
A product containing anti-inflammatory principles from brown seaweeds and a process thereof 5199/CHE/
2012 (Indian patent application).
Anti-inflammatory principles in a preparation of brown seaweeds 4254/DEL/2015 (Indian patent application).
A process to prepare antidiabetic concentrates from seaweeds and a product thereof 3366/DEL/2015 (Indian
patent application).
A process to prepare anti-dyslipidemic concentrate from seaweed and a product therof Application No
201711013741 (Indian patent application).
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